Impact of systemic therapy after stereotactic radiosurgery in patients with limited brain-only metastasis.

ABSTRACT:

Background

The impact of systemic therapy (ST) on outcomes for patients with brain-only metastases (BrM) in the absence of extracranial disease (ECD) is not well established. We compared outcomes between patients with BrM treated with stereotactic radiosurgery (SRS) who received ST ≤3 months (mos), >3 mos, or not at all after SRS.

Methods

We identified BrM patients who completed SRS across two institutions from 1/2015 to 12/2020. Intracranial progression after SRS was determined by brain MRI radiographic recurrence. Overall survival (OS) and intracranial progression free survival (iPFS) estimates were also generated.

Results

In total, 342 patients with BrM were identified. Primary sites included lung (73%), breast (12%), and additional sites (15%). Almost half, 169 (4

SUBMITTER: Qazi JJ 

PROVIDER: S-EPMC12768501 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature